1. Lek Rilutek se dobija besplatno za korisnike obaveznog zdravstvenog osiguranja uz prethodno pozitivno Konzilijarno mišljenje tri neurologa sa Klinike za Neurologiju Kliničkog Centra Srbije. U toku je razmatranje izmene, da pozitvno konzilijrno mišljenje za rilutek, dobijete i na Klinikama za Neurologiju KC Vojvodine u Novom Sadu, KC u Nišu i KC u Kragujevcu. 2. Vitamini, […]
Praktične informacije o zdravstvenim olakšicama Read More »
POŠTOVANI PRIJATELJI, SREĆNI NOVOGODIŠNJI I BOŽIĆNI PRAZNICI! ŽELIMO DA BUDETE BOLJEG ZDRAVLJA U NOVOJ 2025.GODINI I DA PRAZNIKE PROVEDETE U KRUGU SVOJIH NAJMILIJIH. MISLIMO NA VAS I UVEK SMO TU ZA VAS! U IME UDRUŽENJA ZA BOLESTI MOTONEURONA SRBIJE PREDSEDNICA Birtašević Olgica Prof.dr Zorica Stević
Čestitka za Novu 2025.godinu Read More »
Poštovani prijatelji, U proteklom periodu od gotovo tri godine, prošli ste težak period . Gotovo da nema porodice koja nijeimala veliki gubitak. Nažalost, zbog epidemiološke situacije većina vas nije bila u mogućnosti da dobije adekvatnu pomoć lekara. Zbog toga smo izgubili puno obolelih od amiotrofične lateralne skleroze. Najveći broj obolelih stradao je zbog nemogućnosti da
https://www.youtube.com/watch?v=EWgPeSXJL6c O filmu “Nevidljivi heroji Srbije” Film „Nevidljivi heroji Srbije“, je priča u želji da javnost upozna sa neverovatno hrabrim ljudima, obolelim od amiotrofične lateralne skleroze, koji su vezani za respiratore, zarobljenog tela, jer ne pokreću ni ruke ni noge, ili su to u mogućnosti da čine minimalno, zarobljenog glasa, a blistavog uma. Želeli
Nevidljivi heroji Srbije Read More »
Amylyx Pharmaceuticals has filed an application with the European Medicines Agency seeking the approval of its lead candidate AMX0035 as a treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press release. The marketing authorization request follows similar submissions to Health Canada and the U.S. Food and Drug Administration. U.S. regulators recently
Amylyx Files for European Approval of AMX0035 in Treating ALS Read More »
Poštovani prijatelji, SREĆNI NOVOGODIŠNJI I BOŽIĆNI PRAZNICI! ŽELIMO DA BUDETE BOLJEG ZDRAVLJA U NOVOJ 2022.GODINI I DA PRAZNIKE PROVEDETE U KRUGU SVOJIH NAJMILIJIH. MISLIMO NA VAS I UVEK SMO TU ZA VAS! U IME UDRUŽENJA ZA BOLESTI MOTONEURONA SRBIJE
TQS-168, an investigational therapy being developed by Tranquis Therapeutics, reduced inflammation in mouse and human models of amyotrophic lateral sclerosis (ALS), and prolonged survival in the mice, according to a preclinical study. Based on these findings, Tranquis is moving the therapy into Phase 1 clinical studies. “We believe TQS-168 represents a new class
TQS-168 Found to Reduce Inflammation, Extend Survival in Mice Read More »
“All the Bush League batters Are left to die on the diamond In the stands the home crowd scatters For the turnstiles.” Twice in my post-ALS life, Neil Young’s song “For the Turnstiles” has struck me smack dab in the center of my forehead. As the dust finally settled following my ALS diagnosis,
A Sign of the Times — Could They Be a-Changin’? Read More »
A Phase 2 study of the investigational antibody AT-1501 in treating amyotrophic lateral sclerosis (ALS) has completed patient enrollment in three of its four dosing groups, and is likely to be fully enrolled by year’s end, its developer, Eledon Pharmaceuticals, announced. A total of 54 ALS patients diagnosed in the previous two years are
Phase 2 Safety Trial of AT-1501 Nears Full Enrollment of Patients Read More »
